Answers are grounded in this paper and cite their sources.
The study demonstrates a living therapeutic platform that modulates macrophage activity to treat GVHD while maintaining GVL effects.
This study demonstrates the feasibility of a programmable, OMV-based living therapeutic platform for localized control of macrophage inflammasome activity in the gastrointestinal tract. This strategy achieves potent, local control of GVHD without overt impairment of graft-versus-leukemia (GVL) activity, and presents a novel targeted paradigm for treating gastrointestinal inflammatory disorders.
No takes yet. Share an insight, caveat, or question.
Wan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: